Insmed
Insmed Incorporated is an American biopharmaceutical company focused on developing and commercializing therapies for patients suffering from serious and rare pulmonary diseases. The company's primary commercial product is Arikayce, an liposomal inhaled amikacin formulation approved for refractory Mycobacterium avium complex lung disease. Additionally, Insmed advances a clinical research pipeline targeting bronchiectasis, pulmonary arterial hypertension, and inflammation-driven rare conditions. Its primary revenue drivers stem from product sales of Arikayce to specialty pharmacies, healthcare systems, and pharmaceutical distributors. Insmed holds a specialized market position within the global orphan lung disease sector, targeting unmet medical needs in pulmonology. The primary geographic end markets for its approved products and clinical trials include the United States, Europe, and Japan. Corporate headquarters are situated in Bridgewater, New Jersey, United States. Insmed's common stock is listed on the Nasdaq Global Select Market.
51 of the funds FundTelligence covers report a position in Insmed.
- Legal name
- Insmed Inc.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 51
- Exposure themes
- Respiratory and rare diseases, Treatment, Women's Health
Funds holding Insmed
- Polar Capital Biotechnology Fund — Polar Capital · 5.5 % (largest positions only, October 2026)
- DNB Bioteknologi — DNB · 4.57 % (full portfolio disclosed, September 2026)
- UBS Biotech Equity Fund — UBS · 4.4 % (largest positions only, September 2026)
- C WorldWide Healthcare Select — C WorldWide · 4.0 % (largest positions only, October 2026)
- Fondita Healthcare — Fondita · 3.79 % (largest positions only, October 2026)
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 3.5 % (partially disclosed portfolio, September 2026)
- DNB Fund Women's Health — DNB · 3.09 % (full portfolio disclosed, August 2026)
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 3.09 % (largest positions only, September 2026)
Showing the 8 largest of 51 funds holding it.